Want to see GEHC full AI Analyst Report?
GEHC Stock Chart & Stats
$73.31
-$1.38(-2.22%)
At close: 4:00 PM EDT
$73.31
-$1.38(-2.22%)
Day’s Range― - ―
52-Week Range$58.75 - $89.77
Previous CloseN/A
Volume9.13M
Average Volume (3M)2.71M
Market Cap
$28.94B
Enterprise Value$37.74K
Total Cash (Recent Filing)$2.10B
Total Debt (Recent Filing)$10.09B
Price to Earnings (P/E)18.2
Beta1.36
Next Earnings
Nov 04, 2026EPS Estimate
1.2Next Dividend Ex-DateN/A
Dividend Yield0.22%
Share Statistics
EPS (TTM)3.48
Shares Outstanding451,686,250
10 Day Avg. Volume2,812,268
30 Day Avg. Volume2,710,507
Financial Highlights & Ratios
PEG Ratio4.14
Price to Book (P/B)3.61
Price to Sales (P/S)1.82
P/FCF Ratio24.86
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$79.07Price Target Upside7.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)4.93
Revenue Forecast (FY)$21.72B
Bulls Say, Bears Say
Bulls Say
Backlog And DemandStrong orders, book-to-bill above one, and a record backlog provide durable visibility into future equipment and service revenue. This commercial momentum supports production planning, customer retention, and investment in innovation over the next several quarters.
Pharmaceutical Diagnostics GrowthPDx combines rapid revenue growth with a high operating margin, making it an important source of profitable expansion. Strength in contrast media and radiopharmaceuticals can deepen recurring procedure-linked demand and improve the company’s overall mix.
Improving Balance SheetLower leverage and rebuilt equity improve GE HealthCare’s resilience and financial flexibility compared with prior years. A stronger capital base can support research, product launches, and portfolio actions while reducing the strain that debt places on future cash allocation.
Bears Say
Patient Care Solutions WeaknessPCS is currently a material drag on growth and profitability, with both revenue contraction and negative segment EBIT. Management’s strategic review, including a potential sale, signals that recovery may require significant execution or portfolio changes before results stabilize.
Margin PressureCompany-wide margin compression indicates that pricing and cost actions have not yet fully offset operational weakness and higher input costs. Persistent inflation in memory, oil, freight, and components could limit earnings conversion even if revenue growth remains steady.
Weaker Cash GenerationThe decline in free cash flow reduces internally generated funding for investment, debt reduction, and shareholder returns. Although cash generation remains positive over twelve months, the recent deterioration and refund-related volatility make near-term conversion less dependable.
GE Healthcare Technologies Inc News
GEHC FAQ
What was GE Healthcare Technologies Inc’s price range in the past 12 months?
GE Healthcare Technologies Inc lowest stock price was $58.75 and its highest was $89.77 in the past 12 months.
What is GE Healthcare Technologies Inc’s market cap?
GE Healthcare Technologies Inc’s market cap is $28.94B.
When is GE Healthcare Technologies Inc’s upcoming earnings report date?
GE Healthcare Technologies Inc’s upcoming earnings report date is Nov 04, 2026 which is in 47 days.
How were GE Healthcare Technologies Inc’s earnings last quarter?
GE Healthcare Technologies Inc released its earnings results on Jul 29, 2026. The company reported $1.13 earnings per share for the quarter, beating the consensus estimate of $1.036 by $0.094.
Is GE Healthcare Technologies Inc overvalued?
According to Wall Street analysts GE Healthcare Technologies Inc’s price is currently Undervalued.
Does GE Healthcare Technologies Inc pay dividends?
GE Healthcare Technologies Inc pays a Quarterly dividend of $0.035 which represents an annual dividend yield of 0.22%. See more information on GE Healthcare Technologies Inc dividends here
What is GE Healthcare Technologies Inc’s EPS estimate?
GE Healthcare Technologies Inc’s EPS estimate is 1.2.
How many shares outstanding does GE Healthcare Technologies Inc have?
GE Healthcare Technologies Inc has 451,686,250 shares outstanding.
What happened to GE Healthcare Technologies Inc’s price movement after its last earnings report?
GE Healthcare Technologies Inc reported an EPS of $1.13 in its last earnings report, beating expectations of $1.036. Following the earnings report the stock price went up 12.151%.
Which hedge fund is a major shareholder of GE Healthcare Technologies Inc?
Currently, no hedge funds are holding shares in GEHC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GE Healthcare Technologies Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$79.07 (7.86% Upside)
$79.07 (7.86% Upside)
Blogger Sentiment
Bullish
GEHC Sentiment 89%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Increased
By 12.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.89%
12-Months-Change
Fundamentals
Return on Equity
0.22%
Trailing 12-Months
Asset Growth
4.92%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
GE Healthcare Technologies Inc
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
GEHC Company Deck
GEHC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call showed strong commercial momentum: record orders, backlog, solid revenue growth, PDx outperformance, AIS margin expansion, and progress on new AI-enabled products and Flyrcado ramp. Offsetting these positives were meaningful near-term challenges in Patient Care Solutions (13.5% organic decline and negative segment EBIT), inflationary headwinds (memory, oil, freight), and cash volatility driven by tariff refunds. Management maintained full-year guidance and reiterated medium-term targets, expressing confidence in recovery actions and the innovation pipeline.View all GEHC earnings summariesGEHC Revenue Breakdown
44.82% Imaging
25.96% AVS
14.96% PCS
14.06% PDx
0.19% Other
GEHC Stock 12 Month Forecast
Average Price Target
$79.07
▲(7.86% Upside)
Technical Analysis
Abbott Laboratories
―
Boston Scientific
―
Edwards Lifesciences
―
Koninklijke Philips
―
Medtronic
―
Ownership Overview
0.31% Insiders
33.57% Mutual Funds
27.66% Other Institutional Investors
7.27% Public Companies and
Individual Investors